Diagnostic Value of TLE1 in Synovial Sarcoma: A Systematic Review and Meta-Analysis

Abstract EN

Background.

Synovial sarcoma can present morphologically in multiple forms, including biphasic and monophasic subtypes.

As a result, the histological diagnosis can sometimes be challenging.

Transducin-Like Enhancer 1 (TLE1) is a transcriptional corepressor that normally is involved in embryogenesis and hematopoiesis but is also expressed in certain tumors.

This systematic review examines the potential role of TLE1 as a diagnostic biomarker for the synovial sarcoma.

Materials and Methods.

A literature review and meta-analysis were conducted using the electronic databases Pubmed, the Cochrane Library, and Google Scholar.

Thirteen studies met our eligibility criteria and were selected for in-depth analysis.

Results.

The mean sensitivity and specificity of TLE1 in detecting synovial sarcoma were 94% (95% CI 91%–97%) and 81% (95% CI 72%–91%), respectively, when all studies were aggregated together.

The mean positive predictive value (PPV) of TLE1 was 75% (95% CI 62%–87%), whereas the negative predictive value (NPV) was 96% (95% CI 93%–98%).

Conclusion.

TLE1 is a sensitive and specific marker for synovial sarcoma that can aid in its diagnosis.

Due to its involvement in several relevant signaling pathways, TLE1 might have direct relevance to the pathophysiology of the disease.